UMIN ID: C000000020
Registered date:05/07/2005
Study of fluorouracil, epirubicin and cyclophosphamide followed by docetaxel as preoperative chemotherapy in primary breast cancer (JBCRG-02)
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Primary breast cancer |
| Date of first enrollment | 2004/08/01 |
| Target sample size | 30 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2, q3w x 4 cycles, followed by Docetaxel 100 mg/m2, q3w x 4 cycles as Primary systemic Chemotherapy |
Outcome(s)
| Primary Outcome | Safety, clinical and histologic effect |
|---|---|
| Secondary Outcome | Breast-conserving rate, disease-free survival |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 60years-old |
| Gender | Female |
| Include criteria | |
| Exclude criteria | Hypersensitivity for drug Serious coexisting illness Active double cancer Bilateral breast cancer Male breast cancer Pregnant or postpartum women |
Related Information
| Primary Sponsor | Japan Breast Cancer Research Group(JBCRG) |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Advanced Clinical Research Orginization (ACRO) |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Katsumasa Kuroi |
| Address | 9-4-3F, Nihonbashikoamicho, Chuo-ku, Tokyo 103-0016, Japan Japan 103-0016 |
| Telephone | 03-6264-8873 |
| office@jbcrg.jp | |
| Affiliation | JBCRG Head Office |
| scientific contact | |
| Name | Seigo Nakamura |
| Address | 9-1 Akashi, Chuo-ku, Tokyo Japan |
| Telephone | 03-3534-5151 |
| seigonak@med.showa-u.ac.jp | |
| Affiliation | St Luke's International Hospital Breast Center |